Nucleome Therapeutics Bolsters Leadership with Appointment of Dr. Michelle Morrow as Chief Scientific Officer
“Nucleome Therapeutics, a pioneering UK-based biotech firm focused on decoding non-coding human genetics to address inflammatory diseases, has named Dr. Michelle Morrow as its new Chief Scientific Officer, effective February 23, 2026. With over two decades of experience in drug discovery, development, and R&D strategy across biotech and pharmaceutical sectors, Dr. Morrow brings proven expertise … Read more